COPD: Bevespi Aerosphere gets thumbs up


  • Dawn O'Shea
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

The European Medicines Agency has recommended granting marketing authorisation for the medicinal product Bevespi Aerosphere (glycopyrronium/formoterol fumarate dihydrate) for maintenance treatment in patients with chronic obstructive pulmonary disease (COPD).

Bevespi Aerosphere is a fixed-dose combination of the long-acting beta-2 receptor agonist formoterol fumarate dihydrate and the long-acting muscarinic antagonist glycopyrronium. It will be available as a suspension for inhalation (7.2 micrograms / 5.0 micrograms).

The safety and efficacy of Bevespi Aerosphere were demonstrated in the PINNACLE-1 and PINNACLE-2 randomised double-blind placebo-controlled phase 3 trials which included 2,103 and 1,615 patients, respectively. In both trials, participants received either glycopyrrolate/formoterol (GP/FF) 18/9.6 μg, GP 18 μg, FF 9.6 μg or placebo all twice daily.

At week 24, differences in change from baseline in morning predose trough FEV1 for GP/FF vs placebo, GP and FF were 150 mL, 59 mL and 64 mL in PINNACLE-1 (all P<.0001 and ml in pinnacle-2 p there were no significant safety findings. the incidence of adverse events was similar between treatment arms.>

The EMA opinion will now be sent to the European Commission for final approval.